Better Healthcare Services

betterhealthcare.co.uk

Established in 1998, Better Healthcare is one of the fastest growing care providers in the UK. With a network of offices covering East Anglia, South East of England and London, our team has the expertise to deliver the care you need, from your own home to care home or hospitals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCHERS IN THE US DEVELOP COMPUTER MODEL THAT PREDICTS HOW DRUGS AFFECT HEART RHYTHM

Edexlive | April 11, 2020

news image

Researchers have developed a computer model to screen drugs for unintended cardiac side effects, especially arrhythmia risk. Heart arrhythmia, also known as irregular heartbeat or cardiac dysrhythmia, is a group of conditions where the heartbeat is irregular, too slow, or too fast. "One main reason for a drug being removed from the market is potentially life-threatening arrhythmias. Even drugs developed to treat arrhythmia have ended up actually causing them," said study researcher Col...

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

VERO BIOTECH ANNOUNCES FDA APPROVAL FOR ITS SECOND-GEN GENOSYL DS

VERO Biotech | February 03, 2023

news image

On February 2, 2023, VERO Biotech Inc., a commercial-stage biotechnology company focused on neonatal intensive care and the acute care hospital community, announced that FDA has approved its innovative second-generation GENOSYL® Inhaled Nitric Oxide (iNO) delivery system for use in the operating room with rebreathing anesthesia. The second generation GENOSYL® DS is now the first and only iNO delivery device approved for use in both rebreathing and non-rebreathing anesthesia procedu...

Read More

PHARMA TECH

CAMBREX COMPLETES FIRST PHASE OF $30 MILLION CAPACITY EXPANSION PROJECT IN HIGH POINT, NORTH CAROLINA

Cambrex | September 05, 2022

news image

Cambrex today announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina. The newly constructed space adds analytical and chemical development laboratories totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These laboratories will support the development of APIs to be manufactured in the facility's curre...

Read More

BUSINESS INSIGHTS

ASTELLAS AND MBC BIOLABS ANNOUNCE ASTELLAS FUTURE INNOVATOR PRIZE TO HELP BIOTECH START-UPS ACCELERATE EARLY DRUG DISCOVERY AND RESEARCH EFFORTS

Astellas Pharma Inc. | September 20, 2022

news image

Astellas Venture Management LLC a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab f...

Read More
news image

RESEARCHERS IN THE US DEVELOP COMPUTER MODEL THAT PREDICTS HOW DRUGS AFFECT HEART RHYTHM

Edexlive | April 11, 2020

Researchers have developed a computer model to screen drugs for unintended cardiac side effects, especially arrhythmia risk. Heart arrhythmia, also known as irregular heartbeat or cardiac dysrhythmia, is a group of conditions where the heartbeat is irregular, too slow, or too fast. "One main reason for a drug being removed from the market is potentially life-threatening arrhythmias. Even drugs developed to treat arrhythmia have ended up actually causing them," said study researcher Col...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

VERO BIOTECH ANNOUNCES FDA APPROVAL FOR ITS SECOND-GEN GENOSYL DS

VERO Biotech | February 03, 2023

On February 2, 2023, VERO Biotech Inc., a commercial-stage biotechnology company focused on neonatal intensive care and the acute care hospital community, announced that FDA has approved its innovative second-generation GENOSYL® Inhaled Nitric Oxide (iNO) delivery system for use in the operating room with rebreathing anesthesia. The second generation GENOSYL® DS is now the first and only iNO delivery device approved for use in both rebreathing and non-rebreathing anesthesia procedu...

Read More
news image

PHARMA TECH

CAMBREX COMPLETES FIRST PHASE OF $30 MILLION CAPACITY EXPANSION PROJECT IN HIGH POINT, NORTH CAROLINA

Cambrex | September 05, 2022

Cambrex today announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina. The newly constructed space adds analytical and chemical development laboratories totaling 30,000 square feet and provides future workspace for 85 analytical and chemical development scientists. These laboratories will support the development of APIs to be manufactured in the facility's curre...

Read More
news image

BUSINESS INSIGHTS

ASTELLAS AND MBC BIOLABS ANNOUNCE ASTELLAS FUTURE INNOVATOR PRIZE TO HELP BIOTECH START-UPS ACCELERATE EARLY DRUG DISCOVERY AND RESEARCH EFFORTS

Astellas Pharma Inc. | September 20, 2022

Astellas Venture Management LLC a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab f...

Read More